BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

296.04

-1.30 (-0.44%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	297.34
Open	298.00
Bid	287.00 x 1000
Ask	305.00 x 900
Day's Range	295.00 - 298.38
52 Week Range	249.17 - 370.57
Volume	1,054,714
Avg. Volume	1,717,629

Market Cap	62.467B
Beta	1.16
PE Ratio (TTM)	21.16
EPS (TTM)	13.99
Earnings Date	Jul 23, 2018 - Jul 27, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	349.46

Trade prices are not sourced from all markets

All

News

Press Releases

Investor's Business Daily3 days ago
Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs
PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.
Motley Fool3 days ago
5 Experimental New Drugs That Could Be Worth $47 Billion
Optimism for these research and development projects is higher than all the rest.
GlobeNewswire4 days ago
Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018
CAMBRIDGE, Mass., June 19, 2018-- Biogen today announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on Thursday, June 28, 2018. The live webcast will ...
Market Realist4 days ago
Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial
Zacks4 days ago
PTC Therapeutics' Spinal Muscular Atrophy Study Successful
PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.
Market Realist4 days ago
S&P 500’s Top Losses: Why Biogen Declined
The S&P 500’s top losses on June 18 were: Biogen (BIIB) declined 5.2%. Comcast Corp A (CMCSA) declined 3.8%. AmerisourceBergen (ABC) declined 3.5%. Intel (INTC) declined 3.4%. CVS (CVS) declined 3.4%. Biogen
ACCESSWIRE4 days ago
Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Biogen
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / U.S. markets finished mostly lower on Monday, with the Dow logging its 5th straight decline, on fears of growing trade tensions between the U.S. and China. The ...
Barrons.com5 days ago
After the Bell: Dow Drops 100 Points, but Tariffs Don't Matter…Yet
The Dow Jones Industrial Average dropped more than 100 points today but the loss wasn't nearly as bad as it could have been. For the past two days, the Dow Jones Industrial Average has started off with sizable selloffs, only to rally back. The S&P 500, meanwhile, has barely finished down on those days, and today the Nasdaq Composite didn't even drop.
Motley Fool5 days ago
Why Biogen, Baytex Energy, and Catalyst Biosciences Slumped Today
Find out why good news elsewhere hurt one of these stocks.
GlobeNewswire5 days ago
Biogen Foundation Selects Grantees to Receive $10 Million Investment for STEM Education
The Biogen Foundation today announced the six nonprofits that will share a previously-announced four-year, $10 million grant to drive the development of local STEM (science, technology, engineering, and math) education ecosystems in Cambridge and Somerville. The Biogen Foundation’s STAR Initiative is intended to strengthen and support educational offerings in these cities by helping increase access to STEM resources and opportunities for students currently underrepresented in STEM college or career pathways. The six nonprofits selected by the Biogen Foundation will partner with Cambridge and Somerville public schools, focusing on students in grades 6-12.
Motley Fool5 days ago
Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle
Investors value a new round of data for PTC's spinal muscular atrophy drug.
CNBC5 days ago
Biogen plunges after rival drug for spinal muscular atrophy shows promise
Biogen tumbled 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it. Biogen has a few new drugs in the pipeline, including one that could help the company defend its leadership in MS drug therapy, but these are at least two years away reaching the market. Biogen BIIB tumbled as much as 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it.
Bloomberg5 days ago
PTC Therapeutics Up Most Since 2016 on Rare-Disease Drug Results
PTC Therapeutics Inc. shares rose to their highest price since August 2015 after the company said its experimental drug for spinal muscular atrophy helped the vast majority of babies who got the treatment. Over the weekend the company reported that after 182 days of treatment, 91 percent of babies on the drug improved more than four points on a scale that measures motor milestone developments in patients with a form of spinal muscular atrophy, or SMA. Spinal muscular atrophy is a rare disease that progressively takes away people’s physical strength and their ability to walk, eat and breathe.
Investor's Business Daily5 days ago
Stocks Slide; Intel Downgraded; JD.com Spikes On Google Deal
Stocks slid lower Monday as global markets remained rattled by the U.S.-China trade standoff. China stocks were highly active, however, led by JD.com.
Zacks8 days ago
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
Simply Wall St.9 days ago
Should You Be Tempted To Buy Biogen Inc (NASDAQ:BIIB) Because Of Its PE Ratio?
Biogen Inc (NASDAQ:BIIB) is trading with a trailing P/E of 21.9x, which is lower than the industry average of 28.7x. While BIIB might seem like an attractive stock to buy,Read More...
Zacks10 days ago
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.
Business Wire10 days ago
Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) at EULAR 2018
Samsung Bioepis Co., Ltd. and Biogen (BIIB) today announced pooled analysis results of three anti-tumor necrosis factor (anti-TNF) biosimilars – BENEPALI™ (SB4, etanercept biosimilar), FLIXABI™ (SB2, infliximab biosimilar), and IMRALDI™ (SB5, adalimumab biosimilar) – which will be presented at the Annual European Congress of Rheumatology (EULAR 2018) held June 13–16 in Amsterdam, Netherlands. “Since BENEPALI and FLIXABI launched more than two years ago, they have played an increasingly important role in widening access to life-enhancing treatment options for patients and healthcare systems across Europe,” said Chul Kim, Head of Clinical Sciences Division, Samsung Bioepis.
GlobeNewswire10 days ago
Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
Research includes clinical trial data across broad SMA patient populations, expanding scientific understanding of SMA and SPINRAZA® (nusinersen) Study presented examines neurofilament (pNF-H) as a potential ...
GlobeNewswire11 days ago
Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
Research includes clinical trial data across broad SMA patient populations, expanding scientific understanding of SMA and SPINRAZA ® Study presented examines neurofilament as a potential biomarker for ...
Zacks11 days ago
Alzheimer's Research Stumbles Again: What's the Road Ahead?
The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.
Financial Times12 days ago
[$$] Alzheimer’s cure: a fading hope
Alzheimer’s disease ruins lives. As people live longer, more lives will be ruined every passing year. The brain disorder has done just as much damage to the hopes of medical researchers. While some drugs ...
Barrons.com12 days ago
Biogen Buys $625 Million in Ionis Stock
Biogen (BIIB) completed a pact to collaborate with Ionis Pharmaceuticals (IONS), and bought 11.5 million Ionis shares for $625 million, paying $54.34 each. Biogen also invested $375 million as an upfront payment to Ionis to "jointly discover and develop novel antisense drugs for a broad range of neurological diseases," as stated in a press release. In total, Biogen laid out $1 billion in cash.
Zacks15 days ago
Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset
Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.
Markit15 days ago
See what the IHS Markit Score report has to say about Biogen Inc.
Biogen Inc NASDAQ/NGS:BIIB